Panome Bio’s discovery proteomics platform for biofluids delivers deep, unbiased profiling of proteins across plasma, serum, cerebrospinal fluid, urine, and other biological matrices. Built on high-resolution LC-MS technology, our platform provides exceptional coverage and reproducibility, enabling the detection and relative quantitation of thousands of proteins within complex samples.
Panome Bio’s biofluid proteomics platform supports a wide range of applications including biomarker discovery, drug response studies, disease mechanism research, and translational and clinical investigation.
Pioneering Breakthroughs with Discovery
Panome Bio’s discovery proteomics for biofluids approach utilizes a nanoparticle-based proteomic analysis technology to take a deeper look at the proteome.
The technology allows detection across a broader range of proteins, including low-abundant proteins missed by other approaches, enabling more impactful biomarker discovery. Panome Bio pairs the Seer Proteograph with the Thermo Fisher Orbitrap Astral mass spectrometer to achieve the broadest coverage possible with a high-throughput workflow.
Advantages of our Discovery Proteomics Platform:
- Detects protein variants and post-translational modifications
- Allows for broader coverage by capturing more low-abundance proteins that with traditional methods
- Optimized for biofluids such as plasma, serum, urine, cerebrospinal fluid (CSF), or conditioned culture media of multiple species
- Enables comprehensive and in-depth proteomic profiling
Global Proteomics Analysis of Serum from Health and Colon Cancer Patients
See how untargeted proteomics is applied to Colorectal Cancer
Let’s get started!
Discover the unparalleled advantages of Panome Bio’s advanced proteomics technology. With a comprehensive view of the proteome, the experts at Panome Bio can perform robust proteomics analyses, profile unknown peptide variants, and achieve insights that were previously not possible.
Ready to elevate your research? Connect with us today and transform your proteomics outcomes.